Alexion To Join With AZ Ahead Of US Soliris Biosimilars In 2025
Originator Shifting Patients To Next-Gen Ultomiris
Amgen will be able to launch its US Soliris biosimilar around two years ahead of patent expiry under a settlement agreement. The brand’s manufacturer, Alexion, discussed the threat as AstraZeneca pounced with a $39bn takeover agreement.
